The EU Court of Justice dismisses the appeals of several pharmaceutical companies involved in an agreement seeking to delay the marketing of the generic antidepressant citalopram (Lundbeck)

The Court of Justice dismisses the appeals of a number of manufacturers of medicines involved in an agreement seeking to delay the marketing of the genericantidepressant citalopram* The European Commission had imposed on them fines of almost € 150 million From the late 1970’s, the Danish pharmaceutical company Lundbeck developed and patented an antidepressant medicine containing the active substance known as citalopram. Once its original compound patent expired, Lundbeck continued to hold only a number of secondary patents which offered more limited protection. Manufacturers of generic versions of citalopram were therefore able to plan to enter the market. In 2002 Lundbeck entered into agreements with undertakings active in the production or sale of generic medicines. In return for a

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

European Court of Justice, The EU Court of Justice dismisses the appeals of several pharmaceutical companies involved in an agreement seeking to delay the marketing of the generic antidepressant citalopram (Lundbeck), 25 March 2021, e-Competitions April 2021 - II, Art. N° 100020

Visites 147

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues